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In TAVR patients with small AV annulus, implantation 
of the 23 mm Edwards S3 valve results in higher mean 
gradients and a markedly higher likelihood of a mean 




We queried the Providence St Joseph Health STS/ACC TVT 
Registry database for patients undergoing TAVR for SAVA with 
either the ES23 or ME26 (including both the Evolut R and PRO 
versions) between 2015Q3 and 2018Q1 at 11 hospitals in 6 states 
(AK, CA, MT, OR, TX, WA). Aborted or valve-in-valve cases were 
excluded. Post TAVR echo results before hospital discharge, at 1 
month and at 1year follow-up were examined. In addition to mean 
gradient, we assessed for incidence of high gradient (mean gradient 
of >20 mmHg) and presence of moderate/severe aortic regurgitation 
as these are indicators of structural valve degeneration*. 
Continuous variables are reported as mean + SD and binary 
variables are reported as percentage. Between-group differences were 
analyzed by t-test, Fisher exact, Wilcoxon rank sum or Chi-square 
test whenever appropriate.
*Dvir et al; Circulation. Standardized Definition of Structural Valve Degeneration for 
Surgical and Transcatheter Bioprosthetic Aortic Valves.  2018;137:388–399
Patients with small aortic valve annulus (SAVA) undergoing 
transcatheter aortic valve replacement (TAVR) are prone to higher 
post TAVR trans-valve gradients. In many SAVA patients, the choice 
of TAVR valve commonly involves choosing between the Edwards 
SAPIEN 3 23mm (ES23) or the Medtronic Evolut 26mm (ME26). 
The supra-annular design of the Evolut has been touted as providing 
superior hemodynamics in SAVA. We compared performance of 
these two valves in SAVA, particularly in regard to occurrence of 
elevated trans-valve gradients defined as mean gradient >20 mmHg.
LIMITATIONS
METHODS
Table  3 – Echocardiography Results in ME26 and ES23 Groups
Table 1 – Baseline Demographic, Clinical and Imaging Characteristics
Nonrandomized. Site reported clinical and echo data. No echo or CT core 
lab. Incomplete follow-up, especially at one year.
CONCLUSION
Using the above criteria, we identified 763 SAVA patients treated 
with either ES23 (n=608)  or ME26 (n=155; 68% R/32% PRO). 
Baseline demographic, clinical and pre-TAVR imaging characteristics 
between groups were similar (Table 1). Procedural details are shown 
in Table 2. Compared to the ES23, the ME26 cases required longer 
procedural and fluoroscopy time as well as contrast volume. 
Echocardiographic findings following TAVR pre-discharge and at 1 
month and 1 year for both valve groups are depicted in Table 3 and 
Figures 1 and 2. At all time frames, the ES23 valve was associated 
with a higher mean gradient than the ME26 valve (relative 50-77%) 
which increased over 1 year (p 0.002), while ME26 mean gradients 
were unchanged (p 0.337).  In addition, the proportion of ES23 valves 
with a mean gradient >20 mmHg increased from 8% pre-discharge to 
10% at 1 month and to 16% at 1 year in contrast to the MS26 valves 
(2% at pre-discharge and 1 month; 0% at 1 year). Moderate/severe 
aortic regurgitation was infrequent and similar in both valve groups.
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All ME26 ES23 p-value
Number subjects 763 155 608
Age, mean ± SD 81.8 ± 8.1 81.1 ± 9.2 82.0 ± 7.9 0.299
Female, N (%) 663 (86.9%) 142 (91.6%) 521 (85.7%) 0.051
Race-Caucasian, N (%) 700 (91.7%) 146 (94.2%) 554 (91.1%) 0.214
STS PROM Risk Score, mean ± SD 6.3±3.7 6.3±4 6.3±3.7 0.952
BMI, mean ± SD 28.4±8.0 29.0±8.1 28.2±8.0 0.317
Previous PPM, N (%) 88 (11.5%) 16 (10.3%) 72 (11.8%) 0.597
Previous ICD, N (%) 8 (1.0%) 2 (1.3%) 6 (1.0%) 0.668
Prior PCI, N (%) 229 (30.0%) 45 (29.0%) 184 (30.3%) 0.765
Prior CABG, N (%) 69 (9.1%) 13 (8.4%) 56 (9.2%) 0.745
Prior aortic valve procedure, N (%) 25 (3.3%) 8 (5.2%) 17 (2.8%) 0.14
Prior stroke, N (%) 80 (10.5%) 17 (11.0%) 63 (10.4%) 0.826
Prior transient ischemic attack, N (%) 67 (8.8%) 13 (8.4%) 54 (8.9%) 0.846
H/O peripheral arterial disease, N (%) 220 (28.8%) 53 (34.2%) 167 (27.5%) 0.099
Diabetes, N (%) 264 (34.6%) 59 (38.1%) 205 (33.7%) 0.31
Currently on dialysis, N (%) 26 (3.4%) 8 (5.2%) 18 (3%) 0.178
Chronic lung disease, N (%) 263 (34.6%) 60 (39.2%) 203 (33.4%) 0.18
Left ventricle EF, mean ± SD 61.4±11.4 61.1±12.4 61.4±11.2 0.773
AV peak velocity (m/sec), mean ± SD 4.2±0.7 4.3±0.7 4.2±0.7 0.085
AV mean gradient mmHg, mean ± SD 42.6±14.4 44.1±15 42.2±14.3 0.156
Aortic valve area in cm2, mean ± SD 0.7±0.3 0.7±0.3 0.7±0.3 0.307
AV annulus size in mm, mean ± SD 21.7±1.9 21.8±2.0 21.6±1.8 0.323
In patients with small AV annulus, undergoing TAVR, implantation of the 
ES23 valve, compared to the ME26 valve, is associated with significantly 
higher mean gradients that increased over the 1 year study time frame (71% 
higher than ME26 at 1 month; 77% higher at 1 year). Of note, at 1 month, 
our results are similar to the echo core lab findings for the randomized 
pivotal studies for the ES23 (12.8 + 4.7 mmHg) and the ME26 (8.3 + 3.8).*
Not previously reported, the incidence of high gradient (>20 mmHg 
mean) was markedly more common in the ES23 group and tended to 
increase over the one year study time.  These findings may have important 
implications on development of patient prosthesis mismatch and valve 
durability.
*Hahn PT et al, Comprehensive Echocardiographic Assessment of Normal Transcatheter Valve 
Function .J Am Coll Cardiol Img 2019;12:25–34
ME26 (n=155) ES23 (n=605) P value
Pre-discharge Echo (n=149) (n=587)
Mean gradient (mmHg), mean ± SD 8.4±4.2 12.6±4.8 <0.001
% with mean gradient >20 mmHg, N(%) 3 (2.0%) 49 (8.3%) 0.006
Moderate/severe AI, N(%) 2 (1.3%) 4 (0.7%) 0.608
1 Month Follow-up Echo ME26 (n=133) ES23 (n=522) P value
Mean gradient (mmHg), mean ± SD 7.7±3.9 13.2±4.7 <0.001
% with mean gradient >20 mmHg, N(%) 2 (1.5%) 53 (10.2%) <0.001
Moderate/severe AI, N(%) 3 (2.2%) 8 (1.5%) 0.475
1 Year Follow-up Echo ME26 (n=77) ES23 (n=368) P value
Mean gradient (mmHg), mean ± SD 8.2±3.8 14.5±5.6 <0.001
% with mean gradient >20 mmHg, N(%) 0 (0%) 59 (16.0%) <0.001
Moderate/severe AI, N(%) 0 (0%) 12 (3.2%) 0.234
Table 2 - Procedural Details
All ME26 ES23 p-value
Non-elective procedure, N (%) 50 (6.6%) 11 (7.1%) 39 (6.4%) 0.759
TAVR access site-femoral, N (%) 705 (92.4%) 143 (92.3%) 562 (92.4%) 0.941
Contrast Volume, mean ± SD 96.8±58.4 105.7±56.9 94.7±58.7 0.038
Fluoroscopy time, mean ± SD 14.2±9.1 18.8±8.3 13.1±8.9 <0.001
TAVR procedure time, mean ± SD 81.4±40.8 98.9±44.5 76.9±38.6 <0.001
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